[Maternal phenylketonuria]

J M Matthieu1, O Boulat, N Bianchi

  • 1Laboratoire de neurochimie, Service de pédiatrie, CHUV, Lausanne.

Revue Medicale De La Suisse Romande
|June 13, 2001
PubMed

Insights

Maternal phenylketonuria (PKU) poses risks to fetal development. Strict dietary management before and during pregnancy significantly reduces these risks, ensuring healthy outcomes for mother and child.

Area of Science:

  • Metabolic disorders
  • Maternal-fetal medicine
  • Nutritional science

Background:

  • Phenylketonuria (PKU) is a genetic disorder requiring lifelong dietary management.
  • Maternal PKU presents significant risks to fetal development, including growth retardation and malformations.
  • These risks are directly correlated with maternal blood phenylalanine levels during pregnancy.

Observation:

  • Strict low-protein diet adherence before and during gestation is crucial for mitigating fetal risks.
  • Maintaining maternal phenylalanine levels between 120-250 mumol/l and tyrosine levels between 45-90 mumol/l is recommended.
  • Weekly blood monitoring and regular dietary assessments are essential for effective management.

Findings:

  • Implementing a rigorous dietary regimen can normalize the risk of abnormalities to levels seen in the general population.
  • The case report highlights practical strategies for monitoring pregnancies in women with PKU.
  • Sustaining adequate caloric, vitamin, and mineral intake is vital throughout gestation.

Implications:

  • Effective management of maternal PKU through diet and monitoring can prevent adverse fetal outcomes.
  • This approach underscores the importance of preconception counseling and continuous care for women with metabolic disorders.
  • Optimizing maternal metabolic control leads to improved infant health and developmental trajectories.

Related Concept Videos

Genomic Imprinting and Inheritance02:30

Genomic Imprinting and Inheritance

Diploid organisms inherit genetic material through chromosomes from both parents. Copies of the same gene are known as alleles. In most cases, both alleles are simultaneously expressed and allow various cellular processes to function optimally. If one of the alleles is missing or mutated, the expression of the other allele can compensate; however, this is not true for all genes.
The expression of some genes depends on which parent passed the gene to the offspring, through a phenomenon known as...
Teratogenicity01:07

Teratogenicity

The ability of a drug to produce structural deformations and functional abnormalities in the developing embryo or the fetus is called teratogenicity, and the drug producing this effect is known as a teratogen. Teratogenic effects include stillbirth, miscarriage, intrauterine growth restriction, and neurocognitive delay. A teratogen may affect the embryo at different stages of development, which is important in determining the type and extent of the damage. During blastocyst formation, the early...
Overview of Protein Metabolism01:21

Overview of Protein Metabolism

Proteins are broken down into amino acids during digestion. Unlike fats and carbohydrates, which are stored for later use, proteins are not. Instead, amino acids are either used to produce ATP through oxidation or contribute to the creation of new proteins for the growth and repair of the body. Any surplus amino acids from the diet are converted into glucose or triglycerides rather than excreted.
Amino acids play various roles in the body once they are absorbed into cells. They are restructured...
Inborn Errors of Metabolism01:20

Inborn Errors of Metabolism

Phenylketonuria (PKU) is a protein metabolism disorder characterized by high blood levels of the amino acid phenylalanine. This results from a mutation in the gene responsible for phenylalanine hydroxylase, an enzyme that converts phenylalanine into tyrosine. When this enzyme is deficient, phenylalanine builds up in the blood, leading to symptoms such as vomiting, rashes, seizures, growth deficiency, and severe mental retardation. An early diagnosis and a diet restricting phenylalanine intake...
Pharmacokinetics in Pediatric Patients: Drug Metabolism01:24

Pharmacokinetics in Pediatric Patients: Drug Metabolism

In pediatric care, understanding the nuances of hepatic drug metabolism is crucial, as it significantly differs from that of adults. This divergence is primarily due to the developmental stage of drug-metabolizing enzymes, which affects how medications are processed in the body. In neonates, for instance, the activity of Phase I enzymes—critical for the initial breakdown of drugs—is markedly reduced, functioning at just 20–40% of the levels seen in adults. This reduction poses a challenge in...
Pharmacogenetics of Phase II Enzymes: N-acetyltransferase, Thiopurine S-methyltransferase, UDP-glucuronosyltransferase01:27

Pharmacogenetics of Phase II Enzymes: N-acetyltransferase, Thiopurine S-methyltransferase, UDP-glucuronosyltransferase

Phase II biotransformation reactions are essential for detoxifying and eliminating xenobiotics, including many pharmaceutical compounds. These reactions typically involve conjugation, the covalent attachment of polar endogenous groups such as glucuronic acid, sulfate, methyl, or acetyl moieties to functional groups introduced during Phase I metabolism. The resulting conjugates are more water-soluble, enabling efficient renal or biliary excretion.The major classes of Phase II enzymes include...